“…Immunohistochemical studies have reported EGFR overexpression in 22 -81% of NSCLC tumours depending on the antibody used and cut point that defines overexpression (Veale et al, 1987;Volm et al, 1993;Pfeiffer et al, 1996;Cornianu and Tudose, 1997;Pastorino et al, 1997;Rusch et al, 1997;Fontanini et al, 1998;Greatens et al, 1998;D'Amico et al, 1999;Fu et al, 1999;Cox et al, 2000;Ohsaki et al, 2000;Selvaggi et al, 2002;Hirsch et al, 2003;Kanematsu et al, 2003;Mukohara et al, 2003;Onn et al, 2003). The majority of these studies have failed to demonstrate an association with prognosis (Table 1).…”